Response and resistance to cancer immunotherapy are driven by complex immune-immune cell interactions within tumors. Voyant Bio leverages AI-powered microscopy and spatial analytics on human tumors to design precision immunotherapies targeting immune-immune cell interactions. Our approach unlocks opportunities for transformative therapeutic breakthroughs, aiming to significantly improve cancer patient outcomes.
What is the problem?
To make a transformative clinical impact in cancer, we must harness the power of the immune system. As biopharma struggled to reverse T cell dysfunction, it became clear that we could have much greater leverage by preventing dysfunction in their progenitors. These rare and overlooked immune cells have enormous potential to drive effective therapeutic responses, depending on their physical interactions with other immune cells. Mapping these critical immune-immune interactions to leverage these cells for their extraordinary therapeutic benefit has been a major challenge.
What is their solution?
Our proprietary Precision Medicine platform, Voyant PM, leverages AI-powered microscopy and spatial analytics on patient tumor sections to identify these key interactions. This approach generates a deep mapping of complex cellular interaction dynamics and allows to disentangle the signals engaged within these contexts at much finer granularity than ever before. Our platform then trains explainable machine learning models on this map to characterize unexpected mechanisms of action and identify novel therapeutic interventions. Our findings have become a cornerstone of understanding immune response mechanisms in cancer and were validated in animal models. With wide applicability across various cancer types and the potential for numerous groundbreaking discoveries, our strategy represents a paradigm shift by targeting immune-immune cell engagement.
